-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $23

Benzinga·11/11/2026 13:03:58
Listen to the news
Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $20 to $23.